Pfizer – AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction Management
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Thursday 2nd, July 2026
External Deadline: Tuesday 7th, July 2026
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Geographic Scope: Australia, Canada, Germany, Greece, Japan, Korea, Taiwan
Clinical Area: Antivirals – COVID-19
Link to full RFP: 2026 IM G AI DDI COVID-19 RES
Application Due Date: Jul 7, 2026
Specific Area of Interest: Research projects should address barriers and gaps in delivering outpatient COVID-19 antiviral therapy with nirmatrelvir/ritonavir —particularly ensuring treatment within the recommended time window—by using or developing AI-enabled solutions to determine eligibility and manage drug–drug interactions.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Talita Honorato-Rzeszewicz (Talita.honorato-rzeszewicz@pfizer.com),